Methods of Managing Hepatic Steatosis

Abstract

This disclosure relates to methods of using a specific binding agent that targets alpha4 beta7 integrin to treat or prevent fatty liver diseases such as, hepatic steatosis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). In certain embodiments, a specific binding agent that targets alpha4 beta7 integrin is an antibody. In certain embodiments, antibody that binds alpha4 beta7 integrin is vedolizumab. In certain embodiments, the subject is or is not diagnosed with inflammatory bowel disease.

Dependencies are inferred from the claim text.